Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2023, 167(3):225-235 | DOI: 10.5507/bp.2021.071

Effectiveness of ICD therapy in real clinical practice. The Olomouc ICD Registry

Milos Taborsky1, Tomas Skala1, Marian Fedorco1, Vlastimil Doupal1, Ingrid Sovova1, Jiri Jarkovsky2, 3, Klara Benesova2, 3, Monika Bezdekova2, Marek Vicha1, Josef Danek4, Josef Kautzner5
1 Department of Internal Medicine I - Cardiology, University Hospital Olomouc, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic
2 Institute of Health Information and Statistics of the Czech Republic, Palackeho nam. 4, P.O. BOX 60, 128 01 Praha 2, Czech Republic
3 Institute of Biostatistics and Analyses at the Faculty of Medicine of the Masaryk University (IBA FM MU) in Brno, Czech Republic
4 Department of Cardiology, Central Military Hospital Prague, U Vojenske nemocnice 1200, 169 02 Praha 6, Czech Republic
5 Institute for Clinical and Experimental Medicine, Videnska 1958, 140 21 Praha 4, Czech Republic

Background: Clinical parameters linked to a low benefit of ICD implantation and increased mortality risks are needed for an individualized assessment of potential benefits and risks of ICD implantation.

Methods: Analysis of a prospective registry of all patients hospitalized from 2009 to 2019 in a single centre for a first implantation of any type of ICD.

Results: A total of 2,681 patients were included in the registry. Until the end of follow-up (38.4 ± 29.1 months), 682 (25.4%) patients died. The one-year mortality in all patients, the one-year CV mortality, the three-year mortality in all patients, and the three-year CV mortality were 7.8%, 5.7%, 20.6%, and 14.8%, respectively. There was a statistically significant difference when the subgroups were compared according to the type of cardiomyopathy. No significant difference was found between primary and secondary prevention and between the types of devices. Male gender, age ≥ 75 years, diabetes mellitus, and atrial fibrillation were associated with a significantly increased mortality risk.

Conclusion: In an analysis of a long-term follow-up of 2,681 ICD patients, we found no mortality difference between patients with ischemic or non-ischemic cardiomyopathy and in the device type. A higher mortality risk was found in men, patients older than 75 years, diabetics, and those with atrial fibrillation.

Keywords: implantable cardioverter-defibrillator, heart failure, primary prevention, time to shock, appropriate shock, mortality

Received: September 23, 2021; Revised: December 7, 2021; Accepted: December 8, 2021; Prepublished online: December 17, 2021; Published: September 21, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Taborsky, M., Skala, T., Fedorco, M., Doupal, V., Sovova, I., Jarkovsky, J., ... Kautzner, J. (2023). Effectiveness of ICD therapy in real clinical practice. The Olomouc ICD Registry. Biomedical papers, 167(3), 225-235. doi: 10.5507/bp.2021.071
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346(12):877-83. doi: 10.1056/NEJMoa013474 Go to original source... Go to PubMed...
    2. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH; Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004;350(21):2151-8. doi: 10.1056/NEJMoa033088 Go to original source... Go to PubMed...
    3. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352(3):225-37. doi: 10.1056/NEJMoa043399 Go to original source... Go to PubMed...
    4. Barra S, Providência R, Narayanan K, Boveda S, Duehmke R, Garcia R, Leyva F, Roger V, Jouven X, Agarwal S, Levy WC, Marijon E. Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review. Eur Heart J 2020;41(21):1976-86. doi: 10.1093/eurheartj/ehz773 Go to original source... Go to PubMed...
    5. Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, Dargie HJ, Granger CB, Kjekshus J, Køber L, Latini R, Maggioni AP, Packer M, Pitt B, Solomon SD, Swedberg K, Tavazzi L, Wikstrand J, Zannad F, Zile MR, McMurray JJV. Declining Risk of Sudden Death in Heart Failure. N Engl J Med 2017;377(1):41-51. doi: 10.1056/NEJMoa1609758 Go to original source... Go to PubMed...
    6. Sabbag A, Suleiman M, Laish-Farkash A, Samania N, Kazatsker M, Goldenberg I, Glikson M, Beinart R; Israeli Working Group of Pacing and Electrophysiology. Contemporary rates of appropriate shock therapy in patients who receive implantable device therapy in a real-world setting: From the Israeli ICD Registry. Heart Rhythm 2015;12(12):2426-33. doi: 10.1016/j.hrthm.2015.08.020 Go to original source... Go to PubMed...
    7. Narayanan K, Reinier K, Uy-Evanado A, Teodorescu C, Chugh H, Marijon E, Gunson K, Jui J, Chugh SS. Frequency and determinants of implantable cardioverter defibrillator deployment among primary prevention candidates with subsequent sudden cardiac arrest in the community. Circulation;128(16):1733-8. doi: 10.1161/CIRCULATIONAHA Go to original source...
    8. Olsen T, Jørgensen OD, Nielsen JC, Thøgersen AM, Philbert BT, Johansen JB. Incidence of device-related infection in 97 750 patients: clinical data from the complete Danish device-cohort (1982-2018). Eur Heart J 2019;40(23):1862-69. doi: 10.1093/eurheartj/ehz316 Go to original source... Go to PubMed...
    9. Martens P, Nuyens D, Rivero-Ayerza M, Van Herendael H, Vercammen J, Ceyssens W, Luwel E, Dupont M, Mullens W. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction. Clin Res Cardiol 2019;108(10):1074-82. doi: 10.1007/s00392-019-01440-y Go to original source... Go to PubMed...
    10. Zabel M, Willems R, Lubinski A, Bauer A, Brugada J, Conen D, Flevari P, Hasenfulb G, Svetlosak M, Huikuri HV, Malik M, Palovic N, Schmidt G, Sritharan R, Schologl S, Szavit-Nossan J, Traykov V, Tuinenburg AE, Willich SN, Harden M, Friede T, Hastrup J, Svendsen JH, Sticherling C, Merkely B; and the EU-CERTICD Study Investigators. Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. Eur Heart J 2020:41:3437-47. doi:10.1093/eurheartj/ehaa226 Go to original source... Go to PubMed...
    11. Dagres N, Peek N, Leclercq C, Hindricks G. The PROFID project. Eur Heart J 2020;41(39):3781-82. doi: 10.1093/eurheartj/ehaa645 Go to original source... Go to PubMed...
    12. Packer M. What causes sudden death in patients with chronic heart failure and a reduced ejection fraction? Eur Heart J 2020;41:1757-63. Go to original source... Go to PubMed...
    13. Goldenberg I, Huang DT, Nielsen JC. The role of implantable cardioverter-defibrillators and sudden cardiac death prevention: indications, device selection, and outcome. Eur Heart J 2020;41:2003-11. Go to original source...
    14. Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, Estes NA 3rd, Greenberg H, Hall WJ, Huang DT, Kautzner J, Klein H, McNitt S, Olshansky B, Shoda M, Wilber D, Zareba W; MADIT-RIT Trial Investigators. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 2012;367(24):2275-83. doi: 10.1056/NEJMoa1211107 Go to original source... Go to PubMed...
    15. Blomström-Lundqvist C, Traykov V, Erba PA, Burri H, Nielsen JC, Bongiorni MG, Poole J, Boriani G, Costa R, Deharo JC, Epstein LM, Sa´ghy L, Snygg-Martin U, Starck C, Tascini C, Strathmore N. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020;41:2012-32. Go to original source...
    16. Barra S, Boveda S, Providência R, Sadoul N, Duehmke R, Reitan C, Borgquist R, Narayanan K, Hidden-Lucet F, Klug D, Defaye P, Gras D, Anselme F, Leclercq C, Hermida JS, Deharo JC, Looi KL, Chow AW, Virdee M, Fynn S, Le Heuzey JY, Marijon E, Agarwal S; French-UK-Sweden CRT Network. Adding Defibrillation Therapy to Cardiac Resynchronization on the Basis of the Myocardial Substrate. J Am Coll Cardiol 2017;69(13):1669-78. doi: 10.1016/j.jacc.2017.01.042 Go to original source... Go to PubMed...
    17. Amara N, Boveda S, Defaye P, Klug D, Treguer F, Amet D, Perier MC, Gras D, Algalarrondo V, Bouzeman A, Piot O, Deharo JC, Fauchier L, Babuty D, Bordachar P, Sadoul N, Marijon E, Leclercq C; DAI-PP Investigators. Implantable cardioverter-defibrillator therapy among patients with non-ischaemic vs. ischaemic cardiomyopathy for primary prevention of sudden cardiac death. Europace 2018;20(1):65-72. doi: 10.1093/europace/euw379 Go to original source... Go to PubMed...
    18. Weeke P, Johansen JB, Jørgensen OD, Nielsen JC, Møller M, Videbæk R, Højgaard MV, Riahi S, Jacobsen PK. Mortality and appropriate and inappropriate therapy in patients with ischaemic heart disease and implanted cardioverter-defibrillators for primary prevention: data from the Danish ICD Register. Europace 2013;15(8):1150-7. doi: 10.1093/europace/eut017 Go to original source... Go to PubMed...
    19. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998;32(3):695-703. doi: 10.1016/s0735-1097(98)00297-6 Go to original source... Go to PubMed...
    20. Barra S, Narayanan K, Garcia R, Marijon E. Time to revisit implantable cardioverter-defibrillator implantation criteria in women. Eur Heart J 2020:ehaa970. doi: 10.1093/eurheartj/ehaa970 Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content